Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors - Concepedia

Concepedia

Publication | Closed Access

Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors

82

Citations

16

References

2010

Year

Maki Tanioka, Hiroshi Nokihara, Noboru Yamamoto, Yasuhide Yamada, Kazuhiko Yamada, Yasushi Goto, Toshio Fujimoto, R. Sekiguchi, Kazunori Uenaka, Sophie Callies,

Cancer Chemotherapy and Pharmacology

OncologyMedicineOligonucleotidePathologyMolecular BiologyAdvanced Solid TumorsAntisense OligonucleotideAntisense TherapyAnti-cancer AgentCancer TreatmentMolecular DiagnosticsCancer ResearchNovel TherapyTumor Biology

References

	Year	Citations

Page 1

Page 1